Companies
Explore all the available companies. Are you wondering how to find wonderful businesses at great price? Start from A... or take a look at Compoundeer Ranking.
Bigbear.ai Holdings, Inc.
BigBear.ai is a leading provider of mission-ready AI solutions and services for defense, national security, and critical infrastructure. Customers and partners rely on BigBear.ai's artificial intelligence and predictive analytics capabilities in highly complex, distributed, mission-based operating environments. Headquartered in McLean, Virginia , BigBear.ai is a public company traded on the NYSE under the symbol BBAI. For more information, visit https://bigbear.ai and follow BigBear.ai on LinkedIn: @BigBear.ai and X: @BigBearai. To receive email communications from BigBear.ai , register here .
BBAIBiglari Holdings Inc.
No description
BH-ABilibili Inc.
Bilibili is a Chinese online entertainment platform that is best known for its video-sharing site that resembles YouTube. The site was founded in 2009 and started as a long-form video platform for anime, comics, and gaming, or ACG, content that appealed to Gen Z users. Since then, it has expanded its content on the platform to include a broader range of interests that have attracted Chinese users outside of the Gen Z cohort. The firm generates revenue through five main areas: advertising, mobile games, live streaming, value-added services, and e-commerce.
BILIBill Holdings, Inc.
Bill.com Holdings Inc is a provider of cloud-based software which automates complex back-office financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
BILLBillion Group Holdings Ltd
No description
BGHLBilliontoone, Inc.
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible - detecting and precisely quantifying genetic targets with single-molecule sensitivity. This superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine. We believe our novel smNGS platform technologies, combined with our AI-enhanced integrated workflow, allow us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.
BLLNBimergen Energy Corp
Bimergen Energy Corporation [OTCQB: BESS] is a utility-scale Battery Energy Storage System (BESS) asset owner, project developer, and independent power provider focused on delivering critical power grid stability and reducing energy price volatility. The Company owns 23 development stage BESS projects with a cumulative energy capacity of estimated 2 gigawatts (GW). The company secures project financing and oversees construction of their energy storage projects, while operating partners and institutional counterparties will manage daily energy trading operations under long-term offtake agreements ensuring stable, contract-backed revenue. The company also owns 13 development stage solar energy projects with an anticipated cumulative generation capacity of 1.640 gigawatts (GW).
BESSBimini Capital Management, Inc.
Bimini Capital Management Inc collectively with its subsidiaries functions in the financial services domain in the United States. As a real estate investment trust, the company follows the strategy of investing in mortgage-backed securities of two kinds, namely; traditional pass-through Agency Mortgage-backed securities and structured Agency Mortgage-backed securities.
BMNMBinah Capital Group, Inc.
Binah Capital Group is a leading independent wealth management enterprise, publicly traded on the NASDAQ under the ticker NASDAQ: BCG. The company was created upon the completion of the merger between Wentworth Management Services LLC and Kingswood Acquisition Corp.
BCGBingex Ltd
BingEx Ltd. operates as a non-classified establishment. It intends to provide courier services. The company was founded by Peng Xue and Hongjian Yu in May 2014 and is headquartered in Beijing, China.
FLXBio Essence Corp
Bio Essence Corp develops traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offers special formulated dietary supplements and medical food.
BIOEBio Green Med Solution, Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
BGMSBio Key International Inc
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets advanced fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
BKYIBio-path Holdings, Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
BPTHBio-rad Laboratories, Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
BIOBio-techne Corp
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne productsassistscientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means foraccurateclinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over$1.2 billionin net sales in fiscal 2025 and has approximately 3,100 employees worldwide.
TECHBioadaptives, Inc.
BioAdaptives Inc is engaged in developing research-based clinically validated natural wellness solutions. The firm focuses on the research of primitive cells like stem cells and their derivatives. Its products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages. Its product lines include PrimiCell, a primitive cell activator, PrimiLungs, a lung immune defense product, and PluriPain.
BDPTBioaffinity Technologies, Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers.
BIAFBioage Labs, Inc.
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Azelaprag, our lead product candidate, demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function in preclinical obesity models. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period.
BIOABioatla, Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
BCABBiocardia, Inc.
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.
BCDABioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp is a fully-integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants and fertilizers. The company has developed a multi-discipline and multi-product platform capable of providing solutions throughout the entire crop cycle, from pre-planting to transportation and storage. The business divisions consist of crop protection, seed and integrated products, and crop nutrition. Its product includes fertilizers, inoculants, adjuvants, crop protection solutions and seeds.
BIOXBiocorrx Inc.
BioCorRx Inc is an alcohol treatment and rehabilitation company. It is engaged in the development of BioCorRx Recovery Program for the treatment of alcoholism and opioid addiction consisting of a naltrexone implant. It operates within the Specialty Hospitals, Expert Psychiatric industry, specifically within the industry subsets of Alcoholism Rehabilitation Hospital. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment program used to treat both alcohol and opioid addictions.
BICXBiocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
BCRXBiodesix Inc
Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
BDSXBiodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, in Phase 3 development for Familial Adenomatous Polyposis; tolimidone, in Phase 2 development for the treatment of type 1 diabetes; and MTX110, in Phase 1 development in aggressive rare/orphan brain cancer indications.
BDRXBioforce Nanosciences Holdings, Inc.
BioForce Nanosciences Holdings Inc is a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages. It markets its products through social media and telemarketing.
BFNHBiofrontera Inc.
Biofrontera Inc is a biopharmaceutical company specializing in the commercialization of pharmaceutical products for the treatment of dermatological conditions, diseases caused by exposure to sunlight that result in sun damage to the skin. Its licensed products focus on the treatment of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer. It also markets a topical antibiotic for the treatment of impetigo, a bacterial skin infection.
BFRIBiogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
BIIBBioharvest Sciences Inc.
BioHarvest Sciences Inc. (Nasdaq BHST) is a leader in Botanical Synthesis, leveraging its patented technology process to grow plant-based molecules without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals, as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements.
BHST
